Autolus Forced To Slim Down, But Believes CAR-T Has 'Transformational' Potential
Management Reshuffle And 20% Headcount Cut
The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.
The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.